Skip to main content

Prevention of Liver Fibrosis and Cancer in Africa

Objective

Chronic hepatitis B virus (HBV) infection affects 350 million people worldwide and 25-30% of these individuals will die as a result of their infection mainly as a results of hepatocellular carcinoma HCC. Liver cirrhosis, high viral load and dietary exposure to aflatoxin are recognised as risk factors for hepatocellular carcinoma amongst HBV carriers. However, these variables do not account for all cases of HCC and decompensated cirrhosis is rarely ever seen in West Africa suggesting that advanced liver fibrosis may not be an important risk factor in this population. A large case control study on HCC will be used to evaluate the importance of liver fibrosis and other established risk factors in West Africa and to explore other potential oncogenic determinants. The case-control study will generate serum, urine and DNA samples for proteomic, metabonomic and genomic analysis to identify biomarkers and aetiological agents for HCC.
Effective treatment for HBV infection is now available in the developed world but treatment programmes have not been developed for resource poor settings even though some of the effective medication is now available at low cost for HIV management. A trial of HBV treatment in a group of carefully selected high risk patients will be conducted to demonstrate that the incidence of HCC can be reduced in this population as has been observed in Asian patients. The treatment trial will also be used to evaluate the efficacy of screening by ultrasound for early tumours which can be treated with percutaneous alcohol injection.
This comprehensive programme therefore aims to reveal novel aetiological factors for HCC, identify and evaluate biomarkers and demonstrate the efficacy of selective antiviral therapy to prevent HCC

Call for proposal

FP7-AFRICA-2010
See other projects for this call

Coordinator

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
Address
South Kensington Campus Exhibition Road
SW7 2AZ London
United Kingdom

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Tatjana Palalic (Ms.)
EU contribution
€ 642 000

Participants (7)

MEDICAL RESEARCH COUNCIL
United Kingdom
EU contribution
€ 1 105 300
Address
20 Park Crescent
W1B 1AL London

See on map

Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Tumani Corrah (Prof.)
CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER
France
EU contribution
€ 236 000
Address
150 Cours Albert Thomas
69372 Lyon Cedex 08

See on map

Activity type
Research Organisations
Administrative Contact
Olaf Kelm (Dr.)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
EU contribution
€ 158 000
Address
Rue De Tolbiac 101
75654 Paris

See on map

Activity type
Research Organisations
Administrative Contact
Hiba Vergnaud (Ms.)
JOS UNIVERSITY TEACHING HOSPITAL
Nigeria
EU contribution
€ 189 500
Address
Murtala Mohammed Way Plateau State
930001 Jos

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Edith Okeke (Dr.)
UNIVERSITE CHEIKH ANTA DIOP DE DAKAR
Senegal
EU contribution
€ 324 000
Address
Avenue Martin Luther King
- Dakar Fann

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Souleymane Mboup (Prof.)
Ministry of Health and Social Welfare
The Gambia
EU contribution
€ 137 200
Address
The Quadrangle, Banjul
Banjul

See on map

Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Makie Taal (Dr.)
XEPTAGEN SPA
Italy
EU contribution
€ 208 000
Address
Via Delle Industrie 9
30175 Venezia

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Giorgio Fassina (Dr.)